BeiGene | Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies

⟵ Back to Search Results

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Beigene Study ID

BGB-A317-290-LTE1

ClinicalTrials.gov ID

NCT04164199

EudraCT Number

2019-002554-23

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents